Contrave side effects: nausea, the serious warnings, and the honest safety picture

Contrave stands apart from most of what gets written about for weight loss: it is a genuine FDA-approved prescription drug with a full prescribing label, pivotal trials, and a defined safety profile — not a compounded telehealth vial or a gray-market powder. That label is exactly why an honest side-effect page is possible. We can read the common reactions straight from the trial adverse-event tables and the boxed and serious warnings straight from the FDA documentation, rather than guessing. Here is what Contrave actually does to most people, what the serious warnings are, and why the nausea is so front-loaded.

What Contrave is — two old drugs, one new purpose

Contrave is a fixed combination of naltrexone, an opioid-receptor antagonist long used for alcohol and opioid dependence, and bupropion, a norepinephrine- dopamine reuptake inhibitor (NDRI) used as an antidepressant and smoking-cessation aid.^[1]Neither was designed for weight loss; together they act on the brain’s appetite and food-reward circuits. The side-effect profile is, in effect, the combined fingerprint of both molecules — which is why nausea (the combo’s signature) sits alongside the bupropion-specific risks like insomnia and seizures.

The common side effects: nausea leads

Across the pivotal COR (Contrave Obesity Research) trials, the tolerability story is consistent. In COR-I, naltrexone-bupropion produced meaningfully more weight loss than placebo, but nausea was clearly the most common adverse event, reported by a large minority of participants and well above the placebo rate.^[2] COR-II reproduced the same pattern: gastrointestinal events — nausea first, then constipation and vomiting — dominated the side-effect profile, along with headache and dizziness.^[3] The drug’s prescribing label lists the same cluster as the most frequent reactions: nausea, constipation, headache, vomiting, dizziness, insomnia, and dry mouth.^[4]

Why the nausea is front-loaded — and why titration matters

Contrave is not started at the full dose. The label specifies a four-week stepwise escalation — one tablet in week one, building to the maintenance dose of two tablets twice daily by week four.^[4] That schedule exists for one reason: nausea clusters around the dose increases, and ramping up slowly blunts it. The practical implication is the same as with the GLP-1 class — the roughest stretch is the first few weeks, symptoms tend to ease at a steady dose, and trying to skip ahead usually backfires. For the closely related timeline on injectable weight-loss drugs, see our GLP-1 gastrointestinal side-effect timeline.

The serious warnings: this is the part that matters most

Beyond the day-to-day nausea, Contrave carries warnings that change who should take it at all. These come from the bupropion component and from the combination’s effects on the brain and cardiovascular system, and they are spelled out in the prescribing label.^[4]

Is Contrave safe? The honest framing

“Is Contrave safe?” has a defensible answer: for the right person — screened for the contraindications above, titrated slowly, and monitored — it is an approved drug with a characterized profile dominated by manageable, mostly transient gastrointestinal effects. The honest caveats are the two that aren’t about nausea: the neuropsychiatric/suicidality warning and the seizure contraindication are genuine reasons it isn’t for everyone, and the blood- pressure and opioid cautions matter. Read against the reviews and lived reports online, the common thread is that the people who do worst are usually those who escalated too fast or who had a reason the drug shouldn’t have been started at all.

Weigh it against modest efficacy

The side-effect profile only makes sense alongside what Contrave actually delivers, and here the framing has to be honest: the weight loss is modest. In the COR trials, naltrexone-bupropion produced roughly 5–9% weight loss over a year — a real, meaningful result, but well below the double-digit losses seen with the GLP-1 drugs.^[2][3]That ceiling is the context for tolerating the nausea: you are accepting a front-loaded side-effect curve for a smaller payoff than an injectable would give. For the direct head-to-head on effectiveness, see our Contrave vs Wegovy comparison, which lays out the roughly 2.5-fold weight-loss gap rather than re-deriving it here.

The honest bottom line

Contrave’s most common side effect is nausea, concentrated in the first few weeks and the reason for its deliberately slow four-week titration; constipation, headache, dizziness, insomnia, and dry mouth round out the everyday profile. The serious story is the neuropsychiatric/suicidality warning and the seizure contraindication — the parts that decide whether someone should take it at all. And all of it has to be weighed against modest efficacy, well below the GLP-1 class. If you’re comparing options on effectiveness and access, our GLP-1 comparison tool, cost and insurance coverage guide, and provider comparison are the practical next steps.